Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione.
Anne K NorthNina MuftiTheresa SullivanLaurence M CorashPublished in: Transfusion (2020)
PR-RBCCs did not demonstrate genotoxicity in vitro or in vivo and were not carcinogenic in vivo. These studies support the safety of PR-RBCCs and suggest that there is no measurable genotoxic hazard associated with transfusion of PR-RBCCs.